title: A versatile drug delivery system using streptavidin-tagged pegylated liposomes and biotinylated biomaterials.
abstract: Here we have developed a versatile liposome-mediated drug delivery system (DDS) allowing a strong bridge between the streptavidin-tagged liposome (SAL) and biotin (Bi)-tagged biomaterials which has strong affinity to surface proteins expressed in restricted cell lineages. This DDS was effective and specific for many leukemia cells in vitro and in vivo. When examining 6 human leukemia cell lines using calcein-encapsulated SALs in combination with Bi-granulocyte colony-stimulating factor (G-CSF), Bi-anti-CD33 monoclonal antibody (MAb) or Bi-anti-CD7 MAb, the fluorescent positive rate of each cell line was in almost proportion to degree of G-CSF receptor, CD33 or CD7 expression, respectively. More importantly, the binding ability was shown to be well maintained in a mouse xenograft model. Furthermore the cytosine arabinoside (AraC)-encapsulated SALs could kill the corresponding cells much more effectively in combination with Bi-biomaterials than free AraC, as expected. These findings strongly indicate that our SAL/Bi-biomaterial system could allow various types of medical agents to be delivered reliably and stably to the cells targeted.
authors.affiliation: Department of Medicine, National Yang-Ming University Hospital, I-Lan, Taiwan.
authors.forename: Ming-Han
authors.initials: MH
authors.lastname: Chen
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Soda
authors.forename: Kiyoko
authors.initials: K
authors.lastname: Izawa
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Kenzaburo
authors.initials: K
authors.lastname: Tani
authors.forename: Kazuo
authors.initials: K
authors.lastname: Maruyama
authors.forename: Arinobu
authors.initials: A
authors.lastname: Tojo
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Asano
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000378:metabolism*; D019011:Antigens, CD7 / Q000378:metabolism; D001692:Biological Transport; D019921:Biotinylation; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D003561:Cytarabine / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005452:Fluoresceins / Q000378:metabolism; D005456:Fluorescent Dyes / Q000378:metabolism; D016179:Granulocyte Colony-Stimulating Factor / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D020128:Inhibitory Concentration 50; D019169:Jurkat Cells; D020014:K562 Cells; D007938:Leukemia / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D011092:Polyethylene Glycols / Q000737:chemistry*; D016188:Receptors, Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000378:metabolism; D019809:Streptavidin / Q000737:chemistry*; D013678:Technology, Pharmaceutical / Q000379:methods; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D019011:Antigens, CD7; C571163:CD33 protein, human; D005452:Fluoresceins; D005456:Fluorescent Dyes; D008055:Lipids; D008081:Liposomes; D016188:Receptors, Granulocyte Colony-Stimulating Factor; D063268:Sialic Acid Binding Ig-like Lectin 3; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D011092:Polyethylene Glycols; D019809:Streptavidin; C007740:fluorexon
keywords: Biotin; Drug delivery system; Immunoliposome; Internalization; Streptavidin; Tumor-targeting